Loading...
XSWX
MOLN
Market cap141mUSD
Apr 09, Last price  
3.04CHF
1D
7.00%
1Q
-34.76%
Jan 2017
-87.06%
IPO
-85.86%
Name

Molecular Partners AG

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
22.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.71%
Rev. gr., 5y
-24.59%
Revenues
5m
-29.38%
32,417,67926,625,06129,119,20923,040,00020,016,00010,355,00020,383,0009,344,0009,330,000189,556,0007,038,0004,970,000
Net income
-54m
L-12.81%
7,141,512-2,282,756-148,823-18,612,000-25,430,000-37,036,000-36,288,000-62,764,000-63,785,000117,853,000-61,984,000-54,043,000
CFO
-59m
L+0.41%
-13,611,049-11,333,06426,495,500-35,380,000-40,022,000-42,474,000-1,189,000-28,983,000-90,953,000118,566,000-59,005,000-59,248,000
Earnings
Apr 17, 2025

Profile

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
URL
https://www.molecularpartners.com/
IPO date
Oct 22, 2014
Employees
168
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,970
-29.38%
7,038
-96.29%
189,556
1,931.68%
Cost of revenue
65,768
115,623
123,320
Unusual Expense (Income)
NOPBT
(60,798)
(108,585)
66,236
NOPBT Margin
34.94%
Operating Taxes
2
(1,240)
Tax Rate
NOPAT
(60,800)
(108,585)
67,476
Net income
(54,043)
-12.81%
(61,984)
-152.59%
117,853
-284.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
17,342
31
(381)
BB yield
-10.73%
-0.02%
0.17%
Debt
Debt current
1,217
1,208
1,198
Long-term debt
3,671
6,096
8,502
Deferred revenue
3,637
Other long-term liabilities
4,879
5,063
2,552
Net debt
(144,551)
(179,585)
(239,444)
Cash flow
Cash from operating activities
(59,248)
(59,005)
118,566
CAPEX
(705)
(575)
(1,417)
Cash from investing activities
40,486
44,637
(101,121)
Cash from financing activities
14,433
(1,167)
(1,570)
FCF
(59,317)
(107,031)
68,387
Balance
Cash
149,439
186,889
249,144
Long term investments
Excess cash
149,190
186,537
239,666
Stockholders' equity
(242,257)
(188,120)
(125,157)
Invested Capital
391,217
373,264
371,362
ROIC
18.11%
ROCE
26.90%
EV
Common stock shares outstanding
34,033
32,771
33,266
Price
4.75
13.59%
4.18
-36.18%
6.55
-65.85%
Market cap
161,587
17.97%
136,978
-37.13%
217,889
-63.36%
EV
17,036
(42,607)
(21,555)
EBITDA
(58,429)
(106,165)
68,624
EV/EBITDA
0.40
Interest
25
49
605
Interest/NOPBT
0.91%